ERBB2 and breast cancer: In this cohort study of 527 consecutive patients with HER2‐positive or triple‐negative (T1/T2 and N0/N1) breast cancer who achieved breast pCR after NST, 185 of the 193 (95.9%) patients achieved axillary pCR.